Company / R&D Expense
Vertex Pharmaceuticals R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$3.9B
FY2025
5-year range
$2.5B / $3.9B
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#9 of 210
Health Care
What the data says
Among 210 Health Care companies, Vertex Pharmaceuticals is in the top 4% for r&d expense. R&D Expense has increased for 3 consecutive years, from $2.5B in FY2022 to $3.9B in FY2025.
Based on SEC 10-K filings.
$3.9B in FY2025 with a 5-year CAGR of +16.4%. Top quartile in the Health Care sector.
Improved from $3.2B to $3.9B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.5%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 210This company $3.9B Sector average $644.1M
▼
+506.9% above sector average
Key checks
Key Insights
- Vertex Pharmaceuticals's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +16.4%, indicating consistent growth.
- In FY2025, r&d expense increased 7.7% year-over-year.
- Ranks #9 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.9B | +7.7% |
| FY2024 | $3.6B | +14.8% |
| FY2023 | $3.2B | +24.5% |
| FY2022 | $2.5B | -16.7% |
| FY2021 | $3.1B | +66.8% |
| FY2020 | $1.8B | +4.3% |
| FY2019 | $1.8B | +23.9% |
| FY2018 | $1.4B | +6.9% |
| FY2017 | $1.3B | +26.4% |
| FY2016 | $1.0B | +5.2% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026